{"id":"W7117296119","doi":"10.1016/j.iotech.2025.101450","title":"251P Final results of the FAK-PD1 phase I/IIA study of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"NIH Clinical Center; University of California, San Diego; Genentech; Sierra Oncology; Ipsen; Servier; Weill Cornell Medical College; National Institute for Health and Care Research; Seagen; Sidney Kimmel Comprehensive Cancer Center; Pfizer; Moderna; NuCana; Incyte; Boston Pharmaceuticals; Cancer Research UK; Verastem Oncology; Amgen; Barbara Ann Karmanos Cancer Institute; BeiGene; Les Laboratories Pierre Fabre; Moffitt Cancer Center; Sanofi; Exelixis; Astellas Pharma; Eisai; Thomas Jefferson University; Johns Hopkins University; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Phase (matter); Cancer; Solid tumor; Cytotoxicity","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002125741,0.001146572,0.0009651005,0.0003821708,0.0005839816,0.001231365,0.0008411735,0.001750359,0.006891348],"category_scores_gemma":[0.0007996411,0.0003934152,0.001177992,0.0001786356,0.0004421129,0.0002940956,0.0004516571,0.001926566,0.002302183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001022835,"about_ca_system_score_gemma":0.001452606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002427127,"about_ca_topic_score_gemma":0.004333248,"domain_scores_codex":[0.9994136,0.0001998809,0.00003129207,0.00006433993,0.0001511673,0.0001396651],"domain_scores_gemma":[0.9994496,0.00008604148,0.00003209009,0.00003487501,0.0001159468,0.0002815163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2144213,0.01565322,0.004417522,0.001315639,0.002505181,0.002546239,0.0001718184,0.003531454,0.1628907,0.001451542,0.3498106,0.2412848],"study_design_scores_gemma":[0.2044742,0.2320218,0.05871495,0.0002852514,0.003400809,0.003320236,0.0001344291,0.004081558,0.15517,0.001916999,0.3363363,0.0001433691],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6863329,0.04010978,0.01143401,0.03447973,0.01274022,0.01301192,0.05784782,0.001240493,0.1428031],"genre_scores_gemma":[0.7297167,0.01650814,0.01383585,0.02005379,0.003583398,0.004700373,0.06661545,0.0005476069,0.1444388],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006891348,"threshold_uncertainty_score":0.02305382,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02047705227220095,"score_gpt":0.385868474467102,"score_spread":0.3653914221949011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}